CD20 Antibody and NK Cell Treatment for Multiple Sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This early-stage trial tests a combination treatment—a CD20 antibody (which targets certain immune cells) paired with NK042 cell injection (a type of immune cell therapy)—for people with multiple sclerosis. The goal is to evaluate whether this combination is safe and may help slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting, secondary progressive, or primary progressive multiple sclerosis confirmed by current diagnostic standards
- Your MS disability score (EDSS) is between 2.5 and 6.5 at screening
- You are between 18 and 65 years old, weigh at least 45 kg, and have a healthy BMI (18.0 or higher)
- You have not had an MS relapse (sudden worsening of symptoms) in the past 8 weeks
- You have no other serious infections, HIV, hepatitis B or C (with exceptions), or severe heart, lung, liver, or kidney disease
- You are not currently taking other MS medications (like fingolimod, natalizumab, ocrelizumab, or alemtuzumab) and stopped them at least 3 months ago
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.